BioCentury
ARTICLE | Strategy

Solidifying Takeda’s position

How Ariad deal gets Takeda closer to its $10 billion cancer sales goal

January 14, 2017 2:02 AM UTC

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Ariad Pharmaceuticals Inc. should be the boost the pharma needs to hit $10 billion in cancer sales by 2025, as the biotech’s brigatinib is expected to lead Takeda’s commercial expansion into solid tumors in the U.S.

The Jan. 9 takeout headlined a trio of cancer deals unveiled by Takeda during last week’s JPMorgan Healthcare Conference in San Francisco. ...